Time-kill determination of the bactericidal activity of telavancin and vancomycin against clinical methicillin-resistant Staphylococcus aureus isolates from cancer patients.
The bactericidal activity of vancomycin and telavancin was compared against 4 clinical methicillin-resistant Staphylococcus aureus isolates recently recovered from cancer patients, using minimum bactericidal concentration (MBC):MIC ratios and time-kill studies. All 4 isolates were susceptible to both agents based on individual MIC values. The 2 methodologies for assessing bactericidal activity produced variable results. Telavancin appeared to have somewhat better bactericidal activity than vancomycin based on narrower MBC:MIC ratios. However, based on the results of the time-kill studies, neither agent demonstrated reliable bactericidal activity (defined as a ≥3 log10 reduction of the starting inoculum at the end of 24hours) against these organisms. These findings might be of some therapeutic importance in certain clinical settings and/or specific patient populations (such as febrile neutropenic patients) in whom potent bactericidal activity is either desired or preferred.
['Rolston|Kenneth Vi|KV|', 'Wang|Weiqun|W|', 'Nesher|Lior|L|', 'Smith|Jordan R|JR|', 'Rybak|Michael J|MJ|', 'Prince|Randall A|RA|']
D000617:Aminoglycosides D000900:Anti-Bacterial Agents D006801:Humans D000077427:Lipoglycopeptides D055624:Methicillin-Resistant Staphylococcus aureus D008826:Microbial Sensitivity Tests D009369:Neoplasms D013203:Staphylococcal Infections D013997:Time Factors D014640:Vancomycin
Time-kill Bactericidal activity Telavancin Vancomycin Cancer patients MRSA